Fennec Pharmaceuticals Company Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States.

The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients.

It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014.

Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Fennec Pharmaceuticals Inc.

Country	Canada
Founded	1996
Industry	Biotechnology
Sector	Healthcare
Employees	29
CEO	Rostislav Raykov

Contact Details

Address: 68 TW Alexander Drive Research Triangle Park, British Columbia 27709 United States
Phone	919 636 4530
Website	fennecpharma.com

Stock Details

Ticker Symbol	FRX
Exchange	Toronto Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	CA31447P1009
SIC Code	2836

Key Executives

Name	Position
Rostislav Raykov	Chief Executive Officer and Director
Robert C. Andrade	Chief Financial Officer
Terry Evans	Chief Commercial Officer
Dr. Pierre S. Sayad M.S., Ph.D.	Chief Medical Officer
Christiana Cioffi M.B.A.	Chief Strategy Officer
Mark Gowland	Controller
Lei Fang	President of Pharstat Inc